Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes

DOI: 10.1128/JVI.02309-18

Article Information

DOI

PubMed

Published By

History

Editors and / or Reviewers

^aLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine, Irvine, California, USA
^bDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, California, USA
^cAntigen Discovery Inc., Irvine, California, USA
^dIntracellular Pathogens, Robert Koch-Institute, Berlin, Germany
^eInstitute for Immunology, University of California, Irvine, School of Medicine, Irvine, California, USA

Address correspondence to Lbachir BenMohamed, Lbenmoha{at}uci.edu.
R.S., S.R., P.-G.A.C., and H.V. contributed equally to this article.
Citation Srivastava R, Roy S, Coulon P-G, Vahed H, Prakash S, Dhanushkodi N, Kim GJ, Fouladi MA, Campo J, Teng AA, Liang X, Schaefer H, BenMohamed L. 2019. Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4⁺ and CD8⁺ T_RM cells associated with protection against recurrent genital herpes. J Virol 93:e02309-18. https://doi.org/10.1128/JVI.02309-18.

Rendering graph...